Kaletra 50 mg/1 (Lopinavir and Ritonavir TABLET, FILM COATED) 50 mg/1

Kaletra 50 mg/1 is a combination of lopinavir and ritonavir, used to manage HIV infection. This oral medication is designed to support antiviral therapy, helping to control the virus in the body.

Strength

50 mg/1

Pack Size

120 TABLET, FILM COATED in 1 BOTTLE (0074-6799-22)

Manufacturer / TM Owner

AbbVie Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Kaletra 50 mg/1 is primarily used as part of antiretroviral therapy to treat HIV infection. It works by reducing the amount of HIV in the body, which helps to improve immune function and lower the risk of HIV-related complications. This medication is often prescribed in combination with other HIV drugs to enhance effectiveness.

Side Effects

Common effects of Kaletra 50 mg/1 may include nausea, diarrhea, and headache. Some individuals might experience changes in taste, vomiting, or abdominal pain. These effects vary and are not experienced by everyone taking the medication.

Precautions & Warnings

Kaletra 50 mg/1 should be handled with care, especially for individuals with liver or kidney problems. It is important to follow the advice of a healthcare provider regarding its use. Pregnant or breastfeeding women should consult a healthcare professional before taking this medication.

Avoid Interactions

Kaletra 50 mg/1 may interact with other medications, including those metabolized by the liver's cytochrome P450 system. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of this medication.

Frequently Asked Questions

Kaletra 50 mg/1 is used as part of antiretroviral therapy to manage HIV infection by reducing the amount of virus in the body.

Kaletra 50 mg/1 is taken orally, typically with food, as directed by a healthcare provider.

Common side effects may include nausea, diarrhea, headache, and changes in taste.

Kaletra 50 mg/1 may interact with other medications, so it is important to consult a healthcare provider before combining it with other drugs.

Pregnant women should consult a healthcare professional before taking Kaletra 50 mg/1 to assess potential risks and benefits.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.